HUTCHMED (China) Limited (H7T1) - Total Assets
Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) holds total assets worth €1.78 Billion EUR (≈ $2.08 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See HUTCHMED (China) Limited net assets for net asset value and shareholders' equity analysis.
HUTCHMED (China) Limited - Total Assets Trend (2016–2024)
This chart illustrates how HUTCHMED (China) Limited's total assets have evolved over time, based on quarterly financial data.
HUTCHMED (China) Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
HUTCHMED (China) Limited's total assets of €1.78 Billion consist of 83.7% current assets and 16.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.1% |
| Accounts Receivable | €155.54 Million | 12.2% |
| Inventory | €50.40 Million | 4.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how HUTCHMED (China) Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see H7T1 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HUTCHMED (China) Limited's current assets represent 83.7% of total assets in 2024, an increase from 48.9% in 2016.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, down from 23.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 12.2% of total assets.
HUTCHMED (China) Limited Competitors by Total Assets
Key competitors of HUTCHMED (China) Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
HUTCHMED (China) Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.65 | 2.81 | 3.14 |
| Quick Ratio | 4.65 | 2.68 | 3.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.25 Billion | €674.97 Million | €255.34 Million |
HUTCHMED (China) Limited - Advanced Valuation Insights
This section examines the relationship between HUTCHMED (China) Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.06 |
| Latest Market Cap to Assets Ratio | 1.69 |
| Asset Growth Rate (YoY) | -0.4% |
| Total Assets | €1.27 Billion |
| Market Capitalization | $2.15 Billion USD |
Valuation Analysis
Above Book Valuation: The market values HUTCHMED (China) Limited's assets above their book value (1.69x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: HUTCHMED (China) Limited's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for HUTCHMED (China) Limited (2016–2024)
The table below shows the annual total assets of HUTCHMED (China) Limited from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €1.27 Billion ≈ $1.49 Billion |
-0.44% |
| 2023-12-31 | €1.28 Billion ≈ $1.50 Billion |
+24.32% |
| 2022-12-31 | €1.03 Billion ≈ $1.20 Billion |
-25.00% |
| 2021-12-31 | €1.37 Billion ≈ $1.60 Billion |
+89.56% |
| 2020-12-31 | €724.12 Million ≈ $846.57 Million |
+55.68% |
| 2019-12-31 | €465.12 Million ≈ $543.78 Million |
-12.59% |
| 2018-12-31 | €532.12 Million ≈ $622.10 Million |
-11.01% |
| 2017-12-31 | €597.93 Million ≈ $699.05 Million |
+74.61% |
| 2016-12-31 | €342.44 Million ≈ $400.34 Million |
-- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more